Exhaled Molecular Fingerprinting in Diagnosis and Monitoring: Validating Volatile Promises

Trends in Molecular Medicine

Volumn 21, Issue 10, 2015, Pages 633-644

  Boots, Agnes W ^a   Bos, Lieuwe D ^b   van der Schee, Marc P ^b,c   van Schooten, Frederik Jan ^a   Sterk, Peter J ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Breath; Diagnosis; ENose; GC MS; Metabolomics; Volatile organic compounds

Indexed keywords

BIOLOGICAL MARKER; VOLATILE ORGANIC COMPOUND;

BREATH ANALYSIS; DIAGNOSTIC ACCURACY; DNA FINGERPRINTING; HUMAN; LABORATORY DIAGNOSIS; MOLECULAR MEDICINE; MULTIVARIATE ANALYSIS; REVIEW; SENSOR; SIGNAL PROCESSING; VALIDATION PROCESS; ANIMAL; EXHALATION; METABOLOMICS; MOLECULAR DIAGNOSIS; RESPIRATION DISORDERS;

ANIMALS; BIOMARKERS; EXHALATION; HUMANS; METABOLOMICS; MOLECULAR DIAGNOSTIC TECHNIQUES; RESPIRATION DISORDERS; VOLATILE ORGANIC COMPOUNDS;

EID: 84942520726     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.08.001     Document Type: Review

References (77)

1. Schroedinger E. What's life? 1944, Cambridge University Press.
2. Cesario A., et al. A systems medicine clinical platform for understanding and managing non- communicable diseases. Curr. Pharm. Des. 2014, 20:5945-5956.
3. European Lung White Book 2015, European Respiratory Society, European Respiratory Society, (http://www.erswhitebook.org).
4. Agusti A., et al. Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM Workshop Held in Barcelona on June 12, 2014. Am. J. Respir. Crit. Care Med. 2015, 191:391-401.
5. Wheelock C.E., et al. Application of 'omics technologies to biomarker discovery in inflammatory lung diseases. Eur. Respir. J. 2013, 42:802-825.
6. Besa V., et al. Exhaled volatile organic compounds discriminate patients with chronic obstructive pulmonary disease from healthy subjects. Int. J. Chron. Obstruct. Pulmon. Dis. 2015, 10:399-406.
7. van der Schee M.P., et al. Breathomics in lung disease. Chest 2015, 147:224-231.
8. Sethi S., et al. Clinical application of volatile organic compound analysis for detecting infectious diseases. Clin. Microbiol. Rev. 2013, 26:462-475.
9. Haick H., et al. Assessment, origin, and implementation of breath volatile cancer markers. Chem. Soc. Rev. 2014, 43:1423-1449.
10. Aksenov A.A., et al. Characterization of volatile organic compounds in human leukocyte antigen heterologous expression systems: a cell's 'chemical odor fingerprint'. Chembiochem 2012, 13:1053-1059.
11. Amann A., et al. The human volatilome: volatile organic compounds (VOCs) in exhaled breath, skin emanations, urine, feces and saliva. J. Breath Res. 2014, 8:034001.
12. Leopold J.H., et al. Glucose prediction by analysis of exhaled metabolites - a systematic review. BMC Anesthesiol. 2014, 14:46.
13. Wlodzimirow K.A., et al. Exhaled breath analysis with electronic nose technology for detection of acute liver failure in rats. Biosens. Bioelectron. 2014, 53:129-134.
14. Boots A.W., et al. The versatile use of exhaled volatile organic compounds in human health and disease. J. Breath Res. 2012, 6:027108.
15. Van Berkel J.J., et al. A profile of volatile organic compounds in breath discriminates COPD patients from controls. Respir. Med. 2010, 104:557-563.
16. Verdam F.J., et al. Non-alcoholic steatohepatitis: a non-invasive diagnosis by analysis of exhaled breath. J. Hepatol. 2013, 58:543-548.
17. Davies M.P., et al. Unique volatolomic signatures of TP53 and KRAS in lung cells. Br. J. Cancer 2014, 111:1213-1221.
18. Fens N., et al. Exhaled breath analysis by electronic nose in airways disease. Established issues and key questions. Clin. Exp. Allergy 2013, 43:705-715.
19. Filipiak W., et al. Comparative analyses of volatile organic compounds (VOCs) from patients, tumors and transformed cell lines for the validation of lung cancer-derived breath markers. J. Breath Res. 2014, 8:027111.
20. Hakim M., et al. Volatile organic compounds of lung cancer and possible biochemical pathways. Chem. Rev. 2012, 112:5949-5966.
21. Gorham K.A., et al. Ethane and n-pentane in exhaled breath are biomarkers of exposure not effect. Biomarkers 2009, 14:17-25.
22. Pleil J.D., et al. Clinical breath analysis: discriminating between human endogenous compounds and exogenous (environmental) chemical confounders. J. Breath Res. 2013, 7:017107.
23. Bos L.D., et al. Volatile metabolites of pathogens: a systematic review. PLoS Pathog. 2013, 9:e1003311.
24. Schulz S., Dickschat J.S. Bacterial volatiles: the smell of small organisms. Nat. Prod. Rep. 2007, 24:814-842.
25. Whiteson K.L., et al. Breath gas metabolites and bacterial metagenomes from cystic fibrosis airways indicate active pH neutral 2,3-butanedione fermentation. ISME J. 2014, 8:1247-1258.
26. Smolinska A., et al. Current breathomics - a review on data pre-processing techniques and machine learning in metabolomics breath analysis. J. Breath Res. 2014, 8:027105.
27. Smolinska A., et al. Profiling of volatile organic compounds in exhaled breath as a strategy to find early predictive signatures of asthma in children. PLoS ONE 2014, 9:e95668.
28. Xia J., et al. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics 2013, 9:280-299.
29. Herbig J., Beauchamp J. Towards standardization in the analysis of breath gas volatiles. J. Breath Res. 2014, 8:037101.
30. van der Schee M.P., et al. Effect of transportation and storage using sorbent tubes of exhaled breath samples on diagnostic accuracy of electronic nose analysis. J. Breath Res. 2013, 7:016002.
31. Bikov A., et al. Standardised exhaled breath collection for the measurement of exhaled volatile organic compounds by proton transfer reaction mass spectrometry. BMC Pulm. Med. 2013, 13:43.
32. Dragonieri S., et al. An electronic nose in the discrimination of patients with asthma and controls. J. Allergy Clin. Immunol. 2007, 120:856-862.
33. Buszewski B., et al. Human exhaled air analytics: biomarkers of diseases. Biomed. Chromatogr. 2007, 21:553-566.
34. Wilson A.D. Advances in electronic-nose technologies for the detection of volatile biomarker metabolites in the human breath. Metabolites 2015, 5:140-163.
35. Mieth M., et al. Automated needle trap heart-cut GC/MS and needle trap comprehensive two-dimensional GC/TOF-MS for breath gas analysis in the clinical environment. Anal. Chem. 2010, 82:2541-2551.
36. Schwoebel H., et al. Phase-resolved real-time breath analysis during exercise by means of smart processing of PTR-MS data. Anal. Bioanal. Chem. 2011, 401:2079-2091.
37. Peters S., et al. Parameter selection for peak alignment in chromatographic sample profiling: objective quality indicators and use of control samples. Anal. Bioanal. Chem. 2009, 394:1273-1281.
38. Pluskal T., et al. MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics 2010, 11:395.
39. Wei X., et al. A method of aligning peak lists generated by gas chromatography high-resolution mass spectrometry. Analyst 2013, 138:5453-5460.
40. Gowda H., et al. Interactive XCMS Online: simplifying advanced metabolomic data processing and subsequent statistical analyses. Anal. Chem. 2014, 86:6931-6939.
41. Craig A., et al. Scaling and normalization effects in NMR spectroscopic metabonomic data sets. Anal. Chem. 2006, 78:2262-2267.
42. de Lacy Costello B., et al. A review of the volatiles from the healthy human body. J. Breath Res. 2014, 8:014001.
43. Broadhurst D.I., Kell D.B. Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics 2006, 2:171-196.
44. Gromski P.S., et al. A tutorial review: metabolomics and partial least squares-discriminant analysis ndash a marriage of convenience or a shotgun wedding. Anal. Chim. Acta 2015, 879:10-23.
45. Baranska A., et al. Profile of volatile organic compounds in exhaled breath changes as a result of gluten-free diet. J. Breath Res. 2013, 7:037104.
46. Vergouwe Y., et al. External validity of risk models: use of benchmark values to disentangle a case-mix effect from incorrect coefficients. Am. J. Epidemiol. 2010, 172:971-980.
47. Montuschi P., et al. The electronic nose in respiratory medicine. Respiration 2013, 85:72-84.
48. Queralto N., et al. Detecting cancer by breath volatile organic compound analysis: a review of array-based sensors. J. Breath Res. 2014, 8:027112.
49. Pereira J., et al. Breath analysis as a potential and non-invasive frontier in disease diagnosis: an overview. Metabolites 2015, 5:3-55.
50. Davies S.J., et al. Breath analysis of ammonia, volatile organic compounds and deuterated water vapor in chronic kidney disease and during dialysis. Bioanalysis 2014, 6:843-857.
51. Minh Tdo C., et al. The clinical potential of exhaled breath analysis for diabetes mellitus. Diabetes Res. Clin. Pract. 2012, 97:195-205.
52. Arasaradnam R.P., et al. Editorial: metabolomic analysis of breath volatile organic compounds - a new scent for inflammatory bowel disease. Aliment. Pharmacol. Ther. 2014, 40:732-733.
53. Kurada S., et al. Review article: breath analysis in inflammatory bowel diseases. Aliment. Pharmacol. Ther. 2015, 41:329-341.
54. Patel N., et al. Metabolomic analysis of breath volatile organic compounds reveals unique breathprints in children with inflammatory bowel disease: a pilot study. Aliment. Pharmacol. Ther. 2014, 40:498-507.
55. Amann A., et al. Analysis of exhaled breath for disease detection. Annu. Rev. Anal. Chem. 2014, 7:455-482.
56. Kolk A.H., et al. Breath analysis as a potential diagnostic tool for tuberculosis. Int. J. Tuberc. Lung Dis. 2012, 16:777-782.
57. Phillips M., et al. Point-of-care breath test for biomarkers of active pulmonary tuberculosis. Tuberculosis 2012, 92:314-320.
58. Syhre M., et al. The scent of Mycobacterium tuberculosis. Part II. Breath. Tuberculosis 2009, 89:263-266.
59. Fens N., et al. Exhaled air molecular profiling in relation to inflammatory subtype and activity in COPD. Eur. Respir. J. 2011, 38:1301-1309.
60. Ibrahim B., et al. Non-invasive phenotyping using exhaled volatile organic compounds in asthma. Thorax 2011, 66:804-809.
61. van der Schee M.P., et al. Predicting steroid responsiveness in patients with asthma using exhaled breath profiling. Clin. Exp. Allergy 2013, 43:1217-1225.
62. Robroeks C.M., et al. Exhaled volatile organic compounds predict exacerbations of childhood asthma in a 1-year prospective study. Eur. Respir. J. 2013, 42:98-106.
63. Collins G.S., et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement. Ann. Inter. Med. 2015, 162:55-63.
64. Bean H.D., et al. Breathprints of model murine bacterial lung infections are linked with immune response. Eur. Respir. J. 2015, 45:181-190.
65. Kistler M., et al. Effects of diet-matrix on volatile organic compounds in breath in diet-induced obese mice. J. Breath Res. 2014, 8:016004.
66. Szymczak W., et al. Online breath gas analysis in unrestrained mice by hs-PTR-MS. Mamm. Genome 2014, 25:129-140.
67. McShane L.M., et al. Criteria for the use of omics-based predictors in clinical trials. Nature 2013, 502:317-320.
68. Sung J., et al. Molecular signatures from omics data: from chaos to consensus. Biotechnol. J. 2012, 7:946-957.
69. Pujol A., et al. Unveiling the role of network and systems biology in drug discovery. Trends Pharm. Sci. 2010, 31:115-123.
70. Knottnerus J.A., Tugwell P. The standards for reporting of diagnostic accuracy. J. Clin. Epidemiol. 2003, 56:1029.
71. Peng G., et al. Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nat. Nanotechnol. 2009, 4:669-673.
72. Lotvall J., et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J. Allergy Clin. Immunol. 2011, 127:355-360.
73. Knottnerus J.A., et al. Evaluation of diagnostic procedures. BMJ 2002, 324:477-480.
74. Lim C., et al. Using a web-based application to define the accuracy of diagnostic tests when the gold standard is imperfect. PLoS ONE 2013, 8:e79489.
75. Aberle D.R., et al. Results of the two incidence screenings in the National Lung Screening Trial. N. Engl. J. Med. 2013, 369:920-931.
76. Boehme C.C., et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011, 377:1495-1505.
77. Dang N.A., et al. Rapid diagnosis of TB using GC-MS and chemometrics. Bioanalysis 2013, 5:3079-3097.